Literature DB >> 25786659

Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal l-methamphetamine administration.

Matthew N Newmeyer1,2, Marta Concheiro1,3, Jose Luiz da Costa1,4, Ronald Flegel5, David A Gorelick1,6, Marilyn A Huestis1.   

Abstract

Methamphetamine is included in drug testing programmes due to its high abuse potential. d-Methamphetamine is a scheduled potent central nervous system stimulant, while l-methamphetamine is the unscheduled active ingredient in the over-the-counter nasal decongestant Vicks® VapoInhaler™. No data are available in oral fluid (OF) and few in plasma after controlled Vicks® VapoInhaler™ administration. We quantified methamphetamine and amphetamine enantiomers in OF collected with two different devices and plasma via a fully validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Additionally, OF were analyzed with an on-site screening device. Sixteen participants received 7 Vicks® VapoInhaler™ doses according to manufacturer's recommendations. Specimens were collected before and up to 32 h after the first dose. No d-methamphetamine or d-amphetamine was detected in any sample. All participants had measurable OF l-methamphetamine with median maximum concentrations 14.8 and 16.1 μg/L in Quantisal™ and Oral-Eze® devices, respectively, after a median of 5 doses. One participant had measurable OF l-amphetamine with maximum concentrations 3.7 and 5.5 μg/L after 6 doses with the Quantisal™ and Oral-Eze® devices, respectively. There were no positive DrugTest® 5000 results. In the cutoff range 20-50 μg/L methamphetamine with amphetamine ≥limit of detection, 3.1-10.1% of specimens were positive; first positive results were observed after 1-4 doses. Two participants had detectable plasma l-methamphetamine, with maximum observed concentrations 6.3 and 10.0 μg/L after 2 and 5 doses, respectively. Positive OF and plasma methamphetamine results are possible after Vicks® VapoInhaler™ administration. Chiral confirmatory analyses are necessary to rule out VapoInhaler™ intake. Implementing a selective d-methamphetamine screening assay can help eliminate false-positive OF results. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Vicks® VapoInhaler™; chiral analysis; methamphetamine; oral fluid; plasma

Mesh:

Substances:

Year:  2015        PMID: 25786659      PMCID: PMC4575236          DOI: 10.1002/dta.1784

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  11 in total

1.  Evaluation of four oral fluid devices (DDS®, Drugtest 5000®, Drugwipe 5+® and RapidSTAT®) for on-site monitoring drugged driving in comparison with UHPLC-MS/MS analysis.

Authors:  Sabina Strano-Rossi; Erika Castrignanò; Luca Anzillotti; Giovanni Serpelloni; Roberto Mollica; Franco Tagliaro; Jennifer P Pascali; Delfina di Stefano; Roberto Sgalla; Marcello Chiarotti
Journal:  Forensic Sci Int       Date:  2012-05-01       Impact factor: 2.395

2.  Determination of l-methamphetamine: a case history.

Authors:  John F Wyman; John T Cody
Journal:  J Anal Toxicol       Date:  2005-10       Impact factor: 3.367

3.  Evaluation of on-site oral fluid screening using Drugwipe-5(+), RapidSTAT and Drug Test 5000 for the detection of drugs of abuse in drivers.

Authors:  Sarah M R Wille; Nele Samyn; Maria del Mar Ramírez-Fernández; Gert De Boeck
Journal:  Forensic Sci Int       Date:  2009-11-12       Impact factor: 2.395

4.  Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent.

Authors:  Matthew N Newmeyer; Marta Concheiro; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2014-07-05       Impact factor: 4.759

5.  Human pharmacology of the methamphetamine stereoisomers.

Authors:  John Mendelson; Naoto Uemura; Debra Harris; Rajneesh P Nath; Emilio Fernandez; Peyton Jacob; E Thomas Everhart; Reese T Jones
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

6.  Performance evaluation of on-site oral fluid drug screening devices in normal police procedure in Germany.

Authors:  Frank Musshoff; Eva Große Hokamp; Ulrich Bott; Burkhard Madea
Journal:  Forensic Sci Int       Date:  2014-02-18       Impact factor: 2.395

7.  Stereoselectivity in the human metabolism of methamphetamine.

Authors:  Linghui Li; Tom Everhart; Peyton Jacob Iii; Reese Jones; John Mendelson
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

8.  Guidelines for research on drugged driving.

Authors:  J Michael Walsh; Alain G Verstraete; Marilyn A Huestis; Jørg Mørland
Journal:  Addiction       Date:  2008-08       Impact factor: 6.526

9.  Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration.

Authors:  Michael L Smith; Daniel C Nichols; Paula Underwood; Zachary Fuller; Matthew A Moser; Ron Flegel; David A Gorelick; Matthew N Newmeyer; Marta Concheiro; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2014-10       Impact factor: 3.367

10.  The clinical pharmacology of intranasal l-methamphetamine.

Authors:  John E Mendelson; Dana McGlothlin; Debra S Harris; Elyse Foster; Tom Everhart; Peyton Jacob; Reese T Jones
Journal:  BMC Clin Pharmacol       Date:  2008-07-21
View more
  2 in total

1.  Over-the-counter provision of emergency contraceptive pills: a systematic review.

Authors:  Kaitlyn Atkins; Caitlin E Kennedy; Ping Teresa Yeh; Manjulaa Narasimhan
Journal:  BMJ Open       Date:  2022-03-14       Impact factor: 3.006

Review 2.  [Research progress on chiral separation of amphetamines, ketamine, cathinones].

Authors:  Wenchuan Tang; Jing Chang; Yuanfeng Wang; Aihua Wang; Ruihua Wang
Journal:  Se Pu       Date:  2021-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.